Editors' ChoiceMEDICINE

Papers of note in Science Translational Medicine 9 (391)

See allHide authors and affiliations

Science Signaling  30 May 2017:
Vol. 10, Issue 481, eaan8307
DOI: 10.1126/scisignal.aan8307

This week’s articles describe a way in which brain metastases can trigger drug resistance in primary breast tumors and a potential therapy for ALS.


No safe haven for metastases

Kodack et al. reveal that neuregulin signaling in the brain triggers HER3-dependent resistance to therapies targeting PI3K or HER2 in metastases from HER2-positive or PIK3CA-mutant breast cancer.


A stepping stone to ALS drug discovery

Imamura et al. analyzed iPSC-derived motor neurons from ALS patients and propose that Src/c-Abl inhibitors may have potential for treating ALS.

Highlighted Articles

Stay Connected to Science Signaling

Navigate This Article